Niki Katsiki1, Željko Reiner2, Eugenia Tedeschi Reiner3, Khalid Al-Rasadi4, Matteo Pirro5, Dimitri P Mikhailidis6, Amirhossein Sahebkar7,8,9. 1. a Second Propedeutic Department of Internal Medicine, Medical School , Aristotle University of Thessaloniki, Hippocration Hospital , Thessaloniki , Greece. 2. b Department of Internal Medicine , University Hospital Centre Zagreb, School of Medicine University of Zagreb , Zagreb , Croatia. 3. c University Hospital Center Sestre Milosrdnice, University of Osijek , Zagreb , Croatia. 4. d Department of Clinical Biochemistry , Sultan Qaboos University Hospital , Muscat , Oman. 5. e Unit of Internal Medicine, Angiology and Arteriosclerosis Diseases, Department of Medicine , University of Perugia , Perugia , Italy. 6. f Department of Clinical Biochemistry , Royal Free Hospital Campus, University College London Medical School, University College London , London , UK. 7. g Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences , Mashhad , Iran. 8. h Neurogenic Inflammation Research Center , Mashhad University of Medical Sciences , Mashhad , Iran. 9. i School of Pharmacy , Mashhad University of Medical Sciences , Mashhad , Iran.
Abstract
OBJECTIVE: Dyslipidemia is commonly associated with endothelial dysfunction and increased cardiovascular risk. Pitavastatin has been shown to reduce total and low-density lipoprotein cholesterol, to increase high-density lipoprotein (HDL)-cholesterol and improve HDL function. Furthermore, several trials explored its effects on flow-mediated dilation (FMD), as an index of endothelial function. The authors evaluated the effect of pitavastatin therapy on FMD. METHODS: The authors performed a systematic review and meta-analysis of all clinical trials exploring the impact of pitavastatin on FMD. The search included PubMed-Medline, Scopus, ISI Web of Knowledge and Google Scholar databases. Quantitative data synthesis was performed using a random-effects model, with weighted mean difference (WMD) and 95% confidence interval (CI) as summary statistics. RESULTS: Six eligible studies comprising 7 treatment arms were selected for this meta-analysis. Overall, WMD was significant for the effect of pitavastatin on FMD (2.45%, 95% CI: 1.31, 3.60, p < 0.001) and the effect size was robust in the leave-one-out sensitivity analysis. CONCLUSION: This meta-analysis of all available clinical trials revealed a significant increase of FMD induced by pitavastatin.
OBJECTIVE:Dyslipidemia is commonly associated with endothelial dysfunction and increased cardiovascular risk. Pitavastatin has been shown to reduce total and low-density lipoprotein cholesterol, to increase high-density lipoprotein (HDL)-cholesterol and improve HDL function. Furthermore, several trials explored its effects on flow-mediated dilation (FMD), as an index of endothelial function. The authors evaluated the effect of pitavastatin therapy on FMD. METHODS: The authors performed a systematic review and meta-analysis of all clinical trials exploring the impact of pitavastatin on FMD. The search included PubMed-Medline, Scopus, ISI Web of Knowledge and Google Scholar databases. Quantitative data synthesis was performed using a random-effects model, with weighted mean difference (WMD) and 95% confidence interval (CI) as summary statistics. RESULTS: Six eligible studies comprising 7 treatment arms were selected for this meta-analysis. Overall, WMD was significant for the effect of pitavastatin on FMD (2.45%, 95% CI: 1.31, 3.60, p < 0.001) and the effect size was robust in the leave-one-out sensitivity analysis. CONCLUSION: This meta-analysis of all available clinical trials revealed a significant increase of FMD induced by pitavastatin.
Authors: Nicola Edwards; Alexander W W Langford-Smith; Benjamin J Parker; Ian N Bruce; John A Reynolds; M Yvonne Alexander; Eoghan M McCarthy; Fiona L Wilkinson Journal: Lupus Sci Med Date: 2018-08-13